Skip to content Skip to footer
Subscribe Now
Alumis & Kaken
NEWS

Alumis and Kaken Pharmaceutical Enter Collaboration & Licencing Deal for ESK-001’s Development & Commercialization in Japan

Shots:Alumis & Kaken have partnered to develop, manufacture, & market ESK-001 for dermatology in Japan, with an option to expand into rheumatology & GI diseasesAs per the deal, Kaken will handle development, approval & marketing of ESK-001 in Japan in exchange for $40M upfront & near-term co-development costs, with ~$140M in milestones & field…
March 25, 2025

Read more

NEWS

STADA and Alvotech Introduces Uzpruvo (Biosimilar, Stelara) Across the EU

Shots:   The company has introduced Uzpruvo, biosimilar of Stelara (ustekinumab) across the EU to treat gastroenterology, dermatology & rheumatology indications. Uzpruvo is available in a pre-filled syringes with a thinner needle & is latex-free to avoid allergic reactions  Further EU launches are expected in the upcoming mos., pending national price approvals through a fully European supply…
July 22, 2024

Read more

Samsung Bioepis
NEWS

Samsung Bioepis Receives EC’s Marketing Authorization for Pyzchiva (Biosimilar, Stelara) to treat Autoimmune disorders

Shots: The EC has granted marketing authorization for Pyzchiva (Biosimilar, Stelara) to treat autoimmune disorders in gastroenterology, dermatology, and rheumatology The approval was based on P-I & P-III studies of Pyzchiva vs Stelara. P-I trial assessing the PK, safety, tolerability & immunogenicity in healthy volunteers, and  P-III trial assessing the efficacy, safety & PK profile…
April 22, 2024

Read more

PharmaShots Interview Janssen’s Alyssa Johnsen Shares Insights on the New Clinical data of Tremfya (guselkumab) Presented at ACR 2021 and Published in Arthritis & Rheumatology
VIEWPOINTS

PharmaShots Interview: Janssen’s Alyssa Johnsen Shares Insights on the New Clinical data of Tremfya (guselkumab) Presented at ACR 2021 and Published in Arthritis & Rheumatology

In an interview with PharmaShots, Alyssa Johnsen, MD, Ph.D., Vice President, Rheumatology and Maternal-Fetal Health Disease Area Leader at Janssen Research & Development shares her views on the P-III DISCOVER-1 & 2 Studies of Tremfya (guselkumab) for the treatment of psoriatic arthritis in ACR 2021 and published in Arthritis & RheumatologyShots:The P-III DISCOVER-1 & 2 trials evaluate Tremfya (SC) vs PBO in 381 & 739…
January 4, 2022

Read more